相关实验视频

Updated: May 5, 2026

Segmentation and Measurement of Fat Volumes in Murine Obesity Models Using X-ray Computed Tomography
13:09

Segmentation and Measurement of Fat Volumes in Murine Obesity Models Using X-ray Computed Tomography

Published on: April 4, 2012

16.0K

在阿拉伯国家对抗肥胖药物的临床研究

Haifa F AlOtaibi1, Hanan N Al Taib1, Shadan AlMuhaidib1

  • 1From the Health Research Center (AlOtaibi, Alnaserallah, Alhazzani), Ministry of Defense Health Services, from the Department of Family Medicine (Al Taib, Alshagrawi, Alalmai, Alodah), Prince Sultan Military Medical City, from the Department of Biostatistics, Epidemiology and Scientific Computing (AlMuhaidib); from the Organ Transplant Center of Excellence (Alqahtani), Liver, Digestive, and Lifestyle Health Research Section, King Faisal Specialist Hospital and Research Center, from the Medical Cities Program (Almufarrih), Ministry of Interior, from the College of Medicine (Alhazzani), King Saud University, Riyadh, from the Department of Critical Care and Internal Medicine (Alhazzani), College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia, and from the Division of Gastroenterology & Hepatology (Alqahtani), Weill Cornell Medicine, New York, the United States of America.

Saudi medical journal
|May 7, 2025
PubMed
概括

本综述总结了阿拉伯国家的抗肥胖药物 (AOM) 研究,发现大多数研究都是观察性的,重点关注较旧的药物. 对于不同阿拉伯人群中较新的AOMs,需要更多的试验.

关键词:
抗肥胖药物 抗肥胖药物阿拉伯国家阿拉伯国家阿拉伯国家肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖范围审查 范围审查审查

更多相关视频

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet13:09

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

3.6K
An Acupoint Catgut-embedding Therapy for Treating Obesity04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

202

相关概念视频

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
372
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
445
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
330